Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Tislelizumab With Platinum Doublet Chemotherapy as Neoadjuvant Therapy for Participants With Initially Unresectable Stage III Non-small Cell Lung Cancer: A Single-arm, Phase II Trial

NCT05611879 is registered in ClinicalTrials.gov with Beijing Tsinghua Chang Gung Hospital as lead sponsor.

NCT NCT05611879
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05611879 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Tislelizumab With Platinum Doublet Chemotherapy as Neoadjuvant Therapy for Participants With Initially Unresectable Stage III Non-small Cell Lung Cancer: A Single-arm, Phase II Trial
Lead sponsor
Beijing Tsinghua Chang Gung Hospital
Phase
Phase 2
Overall status
Unknown status
Start date
March 12, 2023
Completion date
April 30, 2024
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

nsclc, stage iii